Viking Therapeutics said VK2735 maintained up to 97% of weight loss with every-other-week dosing and up to 90% with monthly dosing over 12 weeks. The results matter because the company plans to evaluate less-frequent subcutaneous and oral maintenance approaches intended to expand dosing flexibility and treatment adherence.

Key Highlights

  • No plateau was observed during 21 weeks of weekly induction dosing with VK2735.
  • The maintenance phase showed gastrointestinal adverse-event rates similar to placebo.
  • VK2735 doses were increased every two weeks during the weekly-dosing phase.

Viking Therapeutics (NASDAQ: VKTX) said VK2735 maintained up to 97% of weight loss after subjects moved to every-other-week dosing. Monthly dosing preserved up to 90% of weight loss. The results came from a 12-week maintenance study of the GLP-1/GIP agonist. Weekly dosing at 17.5 mg produced 22% placebo-adjusted weight loss at Week 33. Viking said the findings support less-frequent subcutaneous maintenance regimens for subjects receiving VK2735.

VK2735 Reaches Week 33

The maintenance study followed an induction period in which subjects received weekly VK2735 or placebo. Participants then moved to maintenance regimens with monthly or every-other-week administration for 12 weeks. The 22% placebo-adjusted result at Week 33 followed weekly treatment with VK2735 at 17.5 mg. Viking said no plateau was observed during 21 weeks of weekly induction dosing. The maintenance results covered transitions from weekly treatment to reduced-frequency schedules, including every-other-week and monthly dosing.

Less-Frequent Dosing Preserves Loss

Subjects assigned to every-other-week VK2735 regimens retained up to 97% of their mean weight loss from the weekly induction period. Separation from placebo was observed as early as four weeks after the transition from weekly dosing for both schedules. The maintenance phase also showed gastrointestinal adverse-event rates similar to placebo. Viking described tolerability during maintenance dosing as excellent.

Oral Maintenance Planned

VK2735 is being developed in subcutaneous and oral formulations. The company said the findings may provide patients and clinicians with more flexible maintenance Options and support adherence to treatment.